Cardiac electrophysiological actions of NS-21 and its active metabolite, RCC-36, compared with terodiline.
S Hayashi, T Natsukawa, C Suma, Y Ukai, Y Yoshikuni, K Kimura
Index: Naunyn Schmiedebergs Arch. Pharmacol. 355(5) , 651-8, (1997)
Full Text: HTML
Abstract
Terodiline, an anticholinergic drug with a Ca2+ blocking action, is thought to be associated with torsade de pointes, a serious ventricular tachycardia. NS-21 is a newly developed drug for the treatment of urinary frequency and urinary incontinence and it has pharmacological properties similar to those of terodiline. It remains unknown, however, whether NS-21 and its active metabolite, RCC-36, have any proarrhythmic activity. The electrophysiological properties of NS-21 and RCC-36 were examined in guinea pig ventricular myocytes and were compared with those of terodiline using the whole-cell patch-clamp technique. NS-21, RCC-36 and terodiline inhibited L-type Ca2+ currents in a concentration-dependent manner with IC50 values of 27.0, 27.0 and 33.5 microM, respectively. At a concentration of 10 microM, terodiline inhibited both the time-dependent current and the tail current of the delayed rectifier K+ current, with the latter being significantly inhibited at voltages more positive than +10 mV. In contrast, NS-21 and RCC-36 had almost no effect on either of these currents. Terodiline also inhibited the inward rectifier K+ current significantly at voltages more negative than -100 mV, whereas NS-21 and RCC-36 had little effect. If the proarrhythmic activity of terodiline resulted primarily from the combined inhibition of K+ and Ca2+ currents, one might expect that NS-21 and RCC-36, which inhibit L-type Ca2+ currents without affecting either the delayed rectifier K+ current or the inward rectifier K+ current, would not share the proarrhythmic activities of terodiline.
Related Compounds
Related Articles:
1999-09-01
[J. Pharmacol. Exp. Ther. 290(3) , 1417-26, (1999)]
Comparison of the effects of NS-21 and terodiline on the QTc interval in dogs.
1998-01-01
[Gen. Pharmacol. 30(1) , 137-42, (1998)]
2000-07-01
[Br. J. Clin. Pharmacol. 50(1) , 77-80, (2000)]
Inhibition of cardiac inward-rectifier K+ current by terodiline.
1999-07-01
[Eur. J. Pharmacol. 370(3) , 319-27, (1999)]
2001-01-01
[Xenobiotica 31(8-9) , 633-50, (2001)]